Investigators accessed longitudinal human data from ebola virus vaccination for signals of efficacy against the Bundibugyo species now surging in the Democratic Republic of Congo.
|Articles|April 6, 2023
Gut Diseases Increase After COVID-19 Infection and Hospitalization
Author(s)Rachel Lutz
Investigators determined there is a modest increased risk of long-term gastrointestinal symptoms and IBS following COVID-19 infection.
Advertisement
New-onset disorders of gut-brain interaction should be anticipated following infection with
Investigators from Italy prospectively and consecutively enrolled 883 eligible hospital patients with and without COVID-19 between May and October 2020 to evaluate the long-term consequences of COVID-19 infection on the
Patients involved in the study were evaluated upon hospital admission, as well as after 1, 6, and 12 months post-hospitalization. Using questionnaires, the study participants were assessed for gastrointestinal symptoms, anxiety, and depression.
There were 614 COVID-19 patients included in the analysis. The control group was made up of 269 patients that were admitted to the hospital for reasons other than COVID-19, which included symptoms such as gastroenterological, traumatic, and surgical pertinence.
The study authors explained that compared to non-infected controls, another study they conducted on this subject showed COVID-19 can contribute to diarrhea, nausea, and other
Gastrointestinal symptoms appeared more frequently in patients with COVID-19 compared to controls at baseline, the study authors said, observing almost 40% of controls compared to almost 60% of COVID-19 patients. These COVID-19 patients reported higher rates of nausea, diarrhea, loose stools, urgency, and a lower rate of hard stools compared to control subjects.
After 1 month, COVID-19 patients still showed significantly higher rates of nausea and acid regurgitation, compared to the control patients.
Follow up was completed by 772 patients (548 COVID-19 and 224 controls) at 6 months, and by 623 patients (435 COVID-19 and 188 controls) at 12 months.
At the 6-month mark, COVID-19 patients reported lower rates of flatus, constipation, and hard stools compared to control patients. At this point, there were no significant differences between the groups in terms of epigastric pain syndrome, post-prandial distress syndrome, functional dyspepsia, IBS, and functional diarrhea.
After a year, COVID-19 patients reported significantly lower rates of constipation and hard stools compared to control patients, the study authors reported. But COVID-19 patients had higher rates of IBS at this point, compared to just a single control patient who developed IBS at the 12-month mark. IBS risk was increased among patients in either group with a history of allergies, chronic intake of PPI, dyspnea at hospitalization. Their rate is in line with data from a recent meta-analysis
Depression and anxiety rates were both higher in the COVID-19 patient group compared to the control group, the investigators found.
“COVID-19 is associated with a modest increased risk of long-term gastrointestinal symptoms and IBS,” the study authors wrote. “Given the high prevalence of COVID-19 at the global level, an increase in new-onset disorders of gut-brain interaction should be expected due to COVID-19, especially after hospitalization for this disease. Future studies are needed to improve our understanding of the mechanisms underlying symptom development in these patients, and to identify novel therapeutic strategies to prevent and treat these conditions.”
Advertisement
Related to this article
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Advertisement
Advertisement